QT Imaging, developer of the QTscan, has selected Freedom Ventures B.V., as the exclusive distributor of its 3D breast imaging technology for the European, Middle Eastern, and North African markets.
Meg Donigan, Chief Operating Officer, QT Imaging said: “As a small company, working with an established distribution network provides us global market reach while being able to maintain the level of quality in marketing, sales, technical service, and most importantly patient care, that we have established in the US. Freedom Ventures has the experience to be that partner in this important region.” Freedom Ventures will also assist QT Imaging in securing a CE Mark and manage the registration process in its markets.
The QTscan is an FDA-cleared breast imaging tool, and the company will seek CE marking to provide confidence to the healthcare community that the device meets EU safety, health, and environmental protection requirements before market launch.
Rutger Brest van Kempen, CEO, Freedom Ventures, said: “We’re very excited about the opportunity the radiation-free QTscan has to fill a unique need in the European breast imaging market where women are being screened later and less often due to concerns about radiation. In the Middle East and North Africa, this new technology will also be embraced for its ease of adoption as it requires no costly facilities or special licensing for operators.
Hisham Hasaan, Vice-President for the Middle East and Africa, Freedom Ventures said: “With QTscan we will have a huge opportunity to screen woman, who now have to travel far to hospitals where radiology equipment is available whereas our technologies can be installed virtually anywhere. We will focus on creating regional QTscan centers to bring this unique technology to the masses.